Showing results (991-1000 of 1,035) with videos related to
Sort By:
Pageof 104
The American Journal of Cardiology|December 2, 2022
Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial InfarctionRaviteja R Guddeti, Cristina Sanina, Rajiv Jauhar, et al.Biophysical Reviews|January 21, 2022
Sequence-dependent structural properties of B-DNA: what have we learned in 40 years?Gabriela da Rosa, Leandro Grille, Victoria Calzada, et al.Journal of the American College of Cardiology|May 21, 2022
Definitions and Standardized Endpoints for Treatment of Coronary BifurcationsMattia Lunardi, Yves Louvard, Thierry Lefèvre, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 18, 2022
Definitions and Standardized Endpoints for Treatment of Coronary BifurcationsMattia Lunardi, Yves Louvard, Thierry Lefèvre, et al.Circulation Research|November 9, 2016
PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMIArshed A Quyyumi, Alejandro Vasquez, Dean J Kereiakes, et al.Journal of the Society for Cardiovascular Angiography & Interventions|July 18, 2022
North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital MortalityPayam Dehghani, Christian W Schmidt, Santiago Garcia, et al.Cell Transplantation|November 22, 2015
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN TrialDoris A Taylor, Emerson C Perin, James T Willerson, et al.Circulation|June 15, 2007
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trialDouglas W Losordo, Richard A Schatz, Christopher J White, et al.American Heart Journal|August 10, 2010
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and designJames T Willerson, Emerson C Perin, Stephen G Ellis, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|August 9, 2020
Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United StatesSantiago Garcia, Larissa Stanberry, Christian Schmidt, et al.Pageof 104